Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Dividends Calendar
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team

CombiGene

2,54

 

SEK

 

+3,67 %

Mindre end 1K følgere

COMBI

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Ownership
Investor consensus
Sammenligne
+3,67%
+5,83%
-0,78%
+6,72%
-9,29%
-22,32%
-66,36%
-76,67%
-97,35%

CombiGene's vision is to give patients affected by severe diseases the opportunity for a better life through gene therapy and other forms of advanced treatments. The company's operations have three focus areas: in-licensing of new assets, development of these assets to proof-of-concept, and out-licensing of the assets to a strategic partner for continued development and commercialization. CombiGene is based in Stockholm.

Læs mere
Markedsværdi
50,3 mio. SEK
Aktieomsætning
611,75 t SEK
Omsætning
330 t
EBIT %
-14.309,09 %
P/E
-
Udbytteafkast, %
-
Finanskalender
12.6
2025

Generalforsamling '25

22.8
2025

Delårsrapport Q2'25

13.2
2026

Årsrapport '25

Alle
Selskabsmeddelelser
Eksterne analyser
ViserAlle indholdstyper
Eksterne analyser14.2.2025, 10.01

CombiGene: Making place for new ventures - VH Corp

• All research activities discontinued • Notice of an extraordinary general meeting on February 20, 2025 • Q&A with chairman Luca Di Stefano After a strategic evaluation of its operations, CombiGene’s board decided to discontinue all research activities...

CombiGene
Pressemeddelelse14.2.2025, 08.21

Västra Hamnen Market Focus: CombiGene: Making place for new ventures

CombiGene
Selskabsmeddelelse14.2.2025, 07.50

Year-end report January-December 2024 CombiGene AB (Publ)

CombiGene

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Selskabsmeddelelse28.1.2025, 07.30

Discontinuation of research activities

CombiGene
Selskabsmeddelelse9.1.2025, 15.00

Stockslätten AB acquires all shares from Strategic Partners A/S

CombiGene
Selskabsmeddelelse9.1.2025, 14.50

Clarification regarding the management's role during the restructuring period

CombiGene
Selskabsmeddelelse9.1.2025, 07.45

CombiGene initiates restructuring as part of strategic review to maximize shareholder value

CombiGene
Selskabsmeddelelse17.12.2024, 13.30

CombiGene AB (publ): Nominating committee

CombiGene
Selskabsmeddelelse10.12.2024, 13.50

Bulletin from the Extraordinary General Meeting of CombiGene AB (publ)

CombiGene
Pressemeddelelse2.12.2024, 14.00

CombiGene conducts Extraordinary General Meeting

CombiGene
Selskabsmeddelelse14.11.2024, 14.40

Shareholders’ proposal for election of Board of Directors

CombiGene
Eksterne analyser11.11.2024, 13.39

CombiGene: Strategic consequences after CG01 - VH Corp

* Implementing cost savings and new priorities * New propositions from the main shareholder * Our revised fair value estimate is SEK 8.27 (12.19) per share In our previous analysis, CombiGene was focused on outlicensing the epilepsy project CG01 again...

CombiGene
Selskabsmeddelelse8.11.2024, 08.00

Interim report January – September 2024 for CombiGene AB (publ)

CombiGene
Selskabsmeddelelse1.11.2024, 09.00

NOTICE OF EXTRAORDINARY GENERAL MEETING IN COMBIGENE AB (PUBL)

CombiGene
Selskabsmeddelelse31.10.2024, 17.00

The Board of Directors of CombiGene has received proposals from the Company’s largest shareholder for the Extraordinary General Meeting intended to be convened

CombiGene
Pressemeddelelse30.10.2024, 08.07

BioStock: CombiGene implements cost savings

CombiGene
Eksterne analyser30.10.2024, 06.21

CombiGene: New priorities after strategic decision - VH Corp

* Terminating the CG01 programme * Implementing cost savings to prolong the financial runway * Our fair value estimate is under review Recently, CombiGene announced new priorities in its pipeline and a cost saving programme to prolong its financial runway...

CombiGene
Pressemeddelelse29.10.2024, 15.15

Västra Hamnen Market Focus: CombiGene: New priorities after strategic decision

CombiGene
Selskabsmeddelelse28.10.2024, 07.50

CombiGene Initiates Measures to Extend Liquidity Horizon by Sharpening Strategic Focus on Gene Therapy, Prioritizing Pipeline Assets, and Implementing a Cost Reduction Program

CombiGene
Selskabsmeddelelse30.9.2024, 11.15

CombiGene announces new preclinical research results in the epilepsy project

CombiGene
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Our team
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.